• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗体药物偶联物的靶点选择:关键因素

Antibody-drug conjugate target selection: critical factors.

作者信息

Bander Neil H

机构信息

Weill-Cornell Medical College, Cornell University, New York, NY, USA.

出版信息

Methods Mol Biol. 2013;1045:29-40. doi: 10.1007/978-1-62703-541-5_2.

DOI:10.1007/978-1-62703-541-5_2
PMID:23913139
Abstract

ADC success requires that all three components of the agent function in a near-flawless manner. Equally important is that the target be selected with stringent consideration as the target is the one factor in ADC development that is immutable and beyond the reach of the developer to refine/manipulate. This chapter reviews the critical factors of target selection that must be met if one is to succeed at ADC development.

摘要

抗体药物偶联物(ADC)的成功需要其所有三个组成部分都能近乎完美地发挥作用。同样重要的是,必须严格谨慎地选择靶点,因为靶点是ADC开发中唯一不可改变且开发者无法优化/操控的因素。本章回顾了若要在ADC开发中取得成功必须满足的靶点选择关键因素。

相似文献

1
Antibody-drug conjugate target selection: critical factors.抗体药物偶联物的靶点选择:关键因素
Methods Mol Biol. 2013;1045:29-40. doi: 10.1007/978-1-62703-541-5_2.
2
Prostate cancer target 'moveable'.前列腺癌靶点“可移动”。
Drug Discov Today. 2005 Jul 15;10(14):951-2. doi: 10.1016/S1359-6446(05)03528-2.
3
Antibody-drug conjugate (ADC) clinical pipeline: a review.抗体药物偶联物(ADC)临床研发进程综述
Methods Mol Biol. 2013;1045:1-27. doi: 10.1007/978-1-62703-541-5_1.
4
Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.为抗体药物偶联物疗法选择最佳抗体:内化作用与细胞内定位
Methods Mol Biol. 2013;1045:41-9. doi: 10.1007/978-1-62703-541-5_3.
5
Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.一种抗体药物偶联物PSMA-ADC在患者来源的前列腺癌异种移植模型中的疗效研究。
Prostate. 2015 Feb 15;75(3):303-13. doi: 10.1002/pros.22916. Epub 2014 Oct 18.
6
An Overview of the Current ADC Discovery Landscape.当前 ADC 发现领域概述。
Methods Mol Biol. 2020;2078:1-22. doi: 10.1007/978-1-4939-9929-3_1.
7
Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen.一种与澳瑞他汀偶联的、针对前列腺特异性膜抗原的全人源单克隆抗体具有强大的抗肿瘤活性。
Clin Cancer Res. 2006 Apr 15;12(8):2591-6. doi: 10.1158/1078-0432.CCR-05-2107.
8
Conference report: hot topics in antibody-drug conjugate development.会议报告:抗体药物偶联物研发的热点话题
Bioanalysis. 2013 Dec;5(24):2989-93. doi: 10.4155/bio.13.276.
9
Pharmacokinetics and ADME characterizations of antibody-drug conjugates.抗体药物偶联物的药代动力学和药物代谢动力学特征
Methods Mol Biol. 2013;1045:117-31. doi: 10.1007/978-1-62703-541-5_7.
10
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.前列腺特异性膜抗原导向免疫偶联物MLN2704用于进展性转移性去势抵抗性前列腺癌患者的I期试验。
J Clin Oncol. 2008 May 1;26(13):2147-54. doi: 10.1200/JCO.2007.15.0532. Epub 2008 Mar 24.

引用本文的文献

1
Effectors of the Future: Universal Chimeric Antigen Receptor.未来的效应器:通用嵌合抗原受体
Transfus Med Hemother. 2024 Jul 15;52(1):61-76. doi: 10.1159/000539609. eCollection 2025 Feb.
2
Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology.抗体药物偶联物(ADCs):塑造精准肿瘤学的未来。
Anticancer Agents Med Chem. 2025 Jan 31. doi: 10.2174/0118715206348204241128063329.
3
Antibody-drug conjugates treatment of small cell lung cancer: advances in clinical research.抗体药物偶联物治疗小细胞肺癌:临床研究进展
Discov Oncol. 2024 Aug 1;15(1):327. doi: 10.1007/s12672-024-01171-1.
4
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy.抗体药物偶联物概述:先进的制造工艺与控制策略
Pharm Res. 2024 Mar;41(3):419-440. doi: 10.1007/s11095-023-03649-z. Epub 2024 Feb 17.
5
Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression.通过控制低表达来优化霍奇金淋巴瘤中 CD30 表达的评估。
Histol Histopathol. 2024 Mar;39(3):319-331. doi: 10.14670/HH-18-644. Epub 2023 Jun 21.
6
Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers.靶抗原特性及其对血液系统恶性肿瘤和实体瘤中临床批准的抗体药物偶联物(ADC)的贡献
Cancers (Basel). 2023 Mar 19;15(6):1845. doi: 10.3390/cancers15061845.
7
ncRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery.ncRNAs 在治疗中的应用:基于核酸的药物递送的挑战和局限性。
Int J Mol Sci. 2021 Oct 27;22(21):11596. doi: 10.3390/ijms222111596.
8
Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond.抗体药物偶联物:作用原理及其在肿瘤学及其他领域的应用
Vaccines (Basel). 2021 Sep 29;9(10):1111. doi: 10.3390/vaccines9101111.
9
Stepping forward in antibody-drug conjugate development.抗体偶联药物开发的新进展。
Pharmacol Ther. 2022 Jan;229:107917. doi: 10.1016/j.pharmthera.2021.107917. Epub 2021 Jun 24.
10
Data-Driven Discovery of Molecular Targets for Antibody-Drug Conjugates in Cancer Treatment.癌症治疗中抗体药物偶联物分子靶点的数据驱动发现
Biomed Res Int. 2021 Jan 2;2021:2670573. doi: 10.1155/2021/2670573. eCollection 2021.